Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib plus Fulvestrant in Advanced Breast Cancer
NCT01992952Phase 2Active, not recruiting
- Sponsor
- Velindre University NHS Trust
- Start
- May 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Fulvestrant + Placebo with Fulvestrant + Capivasertib (2 arms). Primary endpoints: Maximum Tolerated Dose at 6 months and Progression-Free Survival. Started May 2014; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01992952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01992952.